Abstract
Developing specific medications to treat (+)-methamphetamine (METH) addiction is a difficult challenge because METH has multiple sites of action that are intertwined with normal neurological function. As a result, no small molecule medication for the treatment of METH addiction has made it through the FDA clinical trials process. With the invention of a new generation of proteinbased therapies, it is now possible to consider treating drug addiction by an entirely different approach. This new approach is based on the discovery of very high affinity anti-METH monoclonal antibodies (mAbs), which are non-addictive and antagonize METH effects from the blood stream without entering the brain. Due to a very long biological half-life, anti-METH mAbs would only need to be administered once every 2-4 weeks, aiding in patient compliance. As a relapse prevention medication, anti-METH mAbs could reduce or prevent the rewarding effects of a relapse to METH use and thereby improve a patient's probability of remaining in therapy and recovering from their addiction. In this review, we discuss the discovery process of anti-METH mAbs, with a focus on the preclinical development leading to high affinity anti-METH mAb antagonists.
Keywords: Addiction, Amphetamines, monoclonal antibodies, pharmacokinetics, rat, vaccines, METH, cognitive behavioral therapy, psychosis, MAB6H4, PCKN
CNS & Neurological Disorders - Drug Targets
Title: Monoclonal Antibodies as Pharmacokinetic Antagonists for the Treatment of (+)-Methamphetamine Addiction
Volume: 10 Issue: 8
Author(s): S. Michael Owens, William T. Atchley, Michael D. Hambuchen, Eric C. Peterson and W. Brooks Gentry
Affiliation:
Keywords: Addiction, Amphetamines, monoclonal antibodies, pharmacokinetics, rat, vaccines, METH, cognitive behavioral therapy, psychosis, MAB6H4, PCKN
Abstract: Developing specific medications to treat (+)-methamphetamine (METH) addiction is a difficult challenge because METH has multiple sites of action that are intertwined with normal neurological function. As a result, no small molecule medication for the treatment of METH addiction has made it through the FDA clinical trials process. With the invention of a new generation of proteinbased therapies, it is now possible to consider treating drug addiction by an entirely different approach. This new approach is based on the discovery of very high affinity anti-METH monoclonal antibodies (mAbs), which are non-addictive and antagonize METH effects from the blood stream without entering the brain. Due to a very long biological half-life, anti-METH mAbs would only need to be administered once every 2-4 weeks, aiding in patient compliance. As a relapse prevention medication, anti-METH mAbs could reduce or prevent the rewarding effects of a relapse to METH use and thereby improve a patient's probability of remaining in therapy and recovering from their addiction. In this review, we discuss the discovery process of anti-METH mAbs, with a focus on the preclinical development leading to high affinity anti-METH mAb antagonists.
Export Options
About this article
Cite this article as:
Michael Owens S., T. Atchley William, D. Hambuchen Michael, C. Peterson Eric and Brooks Gentry W., Monoclonal Antibodies as Pharmacokinetic Antagonists for the Treatment of (+)-Methamphetamine Addiction, CNS & Neurological Disorders - Drug Targets 2011; 10 (8) . https://dx.doi.org/10.2174/187152711799219370
DOI https://dx.doi.org/10.2174/187152711799219370 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Matrixmetalloproteinase Inhibitors: Promising Therapeutic Targets Against Cancer
Current Pharmaceutical Design Salvianolic Acid B Inhibits Atherogenesis of Vascular Cells through Induction of Nrf2-dependent Heme Oxygenase-1
Current Medicinal Chemistry GPCR Crystallization Using Lipidic Cubic Phase Technique
Current Pharmaceutical Biotechnology Para-Tyrosine Supplementation Improves Insulin- and Liraglutide- Induced Vasorelaxation in Cholesterol-Fed Rats
Protein & Peptide Letters Towards Drugs Targeting Multiple Proteins in a Systems Biology Approach
Current Topics in Medicinal Chemistry Trimethylamine: Metabolic, Pharmacokinetic and Safety Aspects
Current Drug Metabolism B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target
Current Molecular Medicine Neuroprotection Against Ischemic / Hypoxic Brain Damage: Blockers of Ionotropic Glutamate Receptor and Voltage Sensitive Calcium Channels
Current Drug Targets Quorum Sensing Inhibitors as Anti-Biofilm Agents
Current Pharmaceutical Design Implications of Nanoscale Based Drug Delivery Systems in Delivery and Targeting Tubulin Binding Agent, Noscapine in Cancer Cells
Current Drug Metabolism Novel Targets for Antiinflammatory and Antiarthritic Agents
Current Pharmaceutical Design Humic Acids as Therapeutic Compounds in Lead Intoxication
Current Clinical Pharmacology Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases
Current Topics in Medicinal Chemistry Cadherins: The Superfamily Critically Involved in Breast Cancer
Current Pharmaceutical Design Anti-Angiogenic Activity of Quercetin and its Derivatives
Letters in Drug Design & Discovery Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Oral Mucosal Immunization: Recent Advancement and Future Prospects
Current Immunology Reviews (Discontinued) Commentary: Perivascular Fat and Improved Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology Prediction of Plasma Concentration-time Profiles of Drugs in Humans from Animals Following Oral Administration: An Allometric Approach
Current Drug Metabolism Multiple Targeting by the Antitumor Drug Tamoxifen: A Structure-Activity Study
Current Medicinal Chemistry - Anti-Cancer Agents